Axoft develops implantable brain-computer interfaces (iBCIs) built from its proprietary bio-inspired Fleuron™ material, designed to improve biocompatibility and neural data quality. Fleuron is reported to be up to 10,000x softer than polyimide, offers greater region access and higher sensor/stimulator density per thread, and reduces signal attenuation versus standard flexible probes. The company has demonstrated first-in-human implants in more than 11 patients and completed a study at The Panama Clinic with four patients undergoing tumor resection, recording cortical and subcortical activity. Axoft has research published in Nature (December 2023 and June 2025) showing scalable single-cell electrophysiology enabled by its materials and interfaces. The company has commercialized Fleuron via an exclusive licensing agreement with Stanford and secured a joint development agreement with Kayaku Advanced Materials, alongside grant funding to build a GMP manufacturing facility. Co-founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft has opened a subsidiary in Grenoble, France, and plans to scale manufacturing and expand engineering, microfabrication and chemistry teams as it advances clinical programs and regulatory work.

Total raised

$63M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2026